Research programme: engineered protease therapeutics - Catalyst Biosciences/MedImmune

Drug Profile

Research programme: engineered protease therapeutics - Catalyst Biosciences/MedImmune

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catalyst Biosciences; MedImmune
  • Developer Catalyst Biosciences
  • Class Enzymes
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 02 Jun 2016 Engineered proteases research programme is still in early research for inflammation and autoimmune disorders
  • 09 Mar 2016 Catalyst Biosciences has patent protection for engineered proteases in USA and other countries (Catalyst Biosciences 10-K, March 2016)
  • 09 Mar 2016 Catalyst Biosciences has patent pending for engineered proteases in USA and other countries (Catalyst Biosciences 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top